For immediate release
Radiant Genomics, Inc. Awarded an SBIR Phase I Grant
Emeryville, CA, January 26, 2015 – Radiant Genomics, Inc. is pleased to announce it has been awarded a Phase I Small Business Industrial Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for the project titled “A Metagenomic Platform to Identify Amphotericin B Analogs.”
“We are pleased with the continued support from the NIH towards our efforts to mine the metagenome for pharmaceutical value,” said Dr. Jeffrey Kim, CSO of Radiant Genomics, Inc. “Amphotericin B is a powerful, broad spectrum antifungal compound that has long been used to treat life-threatening fungal infections. However, use of this important drug is limited by its toxicity to humans, specifically the severe damage it can cause kidneys. Amphotericin B provides an ideal molecule for us to apply and demonstrate the power and utility of Radiant’s metagenomic natural product discovery platform.”
About the Company
Radiant Genomics, Inc. was founded in 2012 with the goal of integrating a range of novel technologies including large-scale sequencing, synthetic biology, bioinformatics, cloud computing, metabolic engineering, and high-throughput analytical chemistry to develop a robust industrial platform for natural product discovery, diversification, and production. Radiant Genomics utilizes this platform to develop products in numerous market categories including pharmaceuticals, agriculture, specialty chemicals, and nutraceuticals.